-- スコシアバンクは、主要先進国通貨すべてに対して米ドル(USD)が引き続き広範に弱含みになると予想しており、カナダドル(CAD)高の見通しを裏付けています。 同行は最新の為替見通しの中で、政策金利の方向性の乖離が依然としてファンダメンタルズ分析の重要な柱であると述べ、USDの見通しは2026年後半から予測期間の終わりである2027年末まで弱含みで推移すると付け加えました。 一方、CADは2024年から2025年にかけての下落基調を反落しつつあり、スコシアバンクの予測目標に向けて「停滞気味の進展」を続けています。 スコシアバンクのグローバル為替担当アソシエイト・ディレクター、エリック・セオレット氏は、CADは1月初旬に新たなサイクル高値を付けたものの、3月初旬に始まった米イラン紛争の初期段階でその上昇分を失ったと述べています。 「カナダドルの最近の上昇により、当社の適正価格推定値に対するディスカウント(米ドル/カナダドルプレミアム)は大幅に縮小しました。ファンダメンタルズはカナダドル高を示唆しており、市場が紛争関連の懸念を払拭するにつれて、中期的にカナダドルが上昇すると予想しています。」 「カナダ銀行の予測も方向性は変わっていませんが、累積75ベーシスポイントの引き締めは2026年に前倒しされ、最終金利は3.00%で据え置かれています。当社の米ドル/カナダドル予測も変更はなく、2026年末までに1.33、2027年末までに1.30を目標としています。」とテオレ氏は付け加えた。 しかし、スコシアバンクは、7月1日のUSMCA(米国・メキシコ・カナダ協定)見直しに向けて、貿易政策の不確実性が依然として大きなリスクであると指摘した。
Related Articles
Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.
Research Alert: CFRA Maintains Hold Rating On Shares Of Ge Healthcare Technologies Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $65 from $87, based on 11.8x our 2027 EPS estimate of $5.51, a sharp discount to the stock's average forward P/E of 18.1x. We cut our 2026 adjusted EPS estimate to $4.86 from $4.96, which stands at the lower end of the reduced guidance range of $4.80-$5.00 (vs. previous $4.95-$5.15). GEHC achieved Q1 organic revenue growth of 2.9% Y/Y, which was at the high end of its expectations. Yet profitability metrics were disappointing with adjusted EPS of $0.99 missing expectations, and the adjusted EBIT margin declining 150 bps Y/Y. This was primarily due to a discrete supplier issue in the PDx business and an unexpected increase in inflationary costs. As a result, GEHC lowered its profit and cash flow outlook, which we view as a prudent move. Strategically, we think GEHC is advancing a strong innovation pipeline, has completed the acquisition of Intelerad, and has announced a reorganization to combine its Imaging and AVS segments into a new segment, which has the potential to accelerate growth.
Research Alert: CFRA Maintains Hold Rating On Shares Of Lennox International Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target to $569 from $559, 21.4x our 2027 EPS estimate (down to $26.57 from $26.62; our 2026 estimate down to $24.14 from $24.51), near LII's three- and five-year historical forward averages of 21.9x and 20.6x, respectively. We think LII faces material near-term operational challenges from residential market softness, escalating tariff-driven cost inflation (~5% vs. prior ~2.5% guidance), and margin compression in its Home Comfort Solutions segment (390-bp decline to 13.3% in Q1). However, these concerns are substantially mitigated by the Building Climate Solutions segment's exceptional performance (38% revenue growth, 300-bp margin expansion to 19.7% in Q1), significantly improved operating cash flow ($16.1M vs. -$35.8M Y/Y) due to inventory normalization. We note an antitrust class action lawsuit, filed in March, alleging price-fixing among HVAC equipment manufacturers since January 2020, posing an additional risk to LII's financial and reputational standing.